Table 2.

A comparison of the clinical and biochemical parameters of CAH patients adherent and non-adherent to treatment both who did or did not developed TART at the time of the last scrotal ultrasound examination (mean ± s.d. or median and range).

	Adherent		TART + no TART	Non-adherent		TART + no TART	P
	TART (3/8)	No TART (6/17)	9/25	TART (5/8)	No TART (11/17)	16/25
Age at evaluation (years)	14.1 ± 1.3	16.2 ± 1.7	15.7 ± 2.6	16.5 ± 2.3	14.6 ± 3.1	15.0 ± 2.7	NS
17OHP (ng/dL) (0.2–2.3)	9.7 ± 2.2	11.1 ± 5.2	10.3 ± 4.1	19.3 ± 1.9	16.3 ± 2.3	17.6 ± 3.4	<0.001
Androstenedione (ng/mL) (0.6–2.7)	16.2 ± 4.3	12.4 ± 4.1	14.2 ± 2.6	20.2 ± 2.3	18.8 ± 4.7	19.6 ± 3.9	<0.01
Testosterone (nmol/L) (8.5–55.5)	32.0 ± 15.3	26.6 ± 15.2	29.8 ± 21.1	30.0 ± 14.2	28.1 ± 12.2	29.1 ± 13.6	NS
Height (SDS)	−1.1 (−0.9/−1.3)	−1.2 (−1.1/1.3)	−1.1 (−0.8/−1.3)	−1.3 (−1.2/−1.4)	−1.3 (−1.0/−1.6)	−1.3 (−1.0/−1.6)	NS
BMI (SDS)	0.42 ± 0.2	0.35 ± 0.6	0.39 ± 0.5	0.52 ± 0.9	0.47 ± 1.3	0.49 ± 1.2	NS
Age at puberty (years)*	12.2 (11.9–13.1)	12.7 (11.6–12.9)	12.5 (11.6–12.0)	11.5 (11.0–12.5)	12.3 (11.6–12.8)	12.1 (11–12.8)	NS

*Puberty was assessed by initial increase of the testicular volume presented as mean and range in brackets.

17OHP, 17OH progesterone; NS, non-significant, normal values are given in brackets; SDS, standard deviation score, TART, testicular adrenal rest tumor.